Discover
JBIO
Jade Biosciences, Inc.
21.81
2 x 15.98
2 x 27.73
bid
ask
-
0.41
1.85%
2 @ 04:00 PM
21.72 -0.09 (0.41%)
| Ytd | 41.35% | |
| 1y | 101.01% |
21.48
day range
22.70
6.67
52 week range
28.00
| Open | 22.38 | Prev Close | 22.22 | Low | 21.48 | High | 22.70 | Mkt Cap | 1.33B |
| Vol | 774.38K | Avg Vol | 979.72K | EPS | -2.63 | P/E | N/A | Forward P/E | -9.75 |
| Beta | N/A | Short Ratio | 4.37 | Inst. Own | 84.82% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 21.45 | 200-d Avg | 15.21 | 1yr Est | 48.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0 | N/A | -0.05 | -9.62% |
| 2026-03-06 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-13 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-11-13 | 2025-09 | 0 | N/A | 0.09 | 15.79% |
| 2025-08-13 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-13 | 2025-06 | 0 | N/A | -0.43 | -100.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-15 | UBS | Upgrade | Buy | |
| 2026-06-02 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-01 | BTIG | Upgrade | Buy | Buy |
| 2026-06-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-27 | BTIG | Upgrade | Buy | Buy |
| 2026-05-11 | Guggenheim | Upgrade | Buy | Buy |
Profile
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-11 | BEKIROGLU ELIZABETH | Officer | 28.13K | Stock Award(Grant) |
| 2026-02-11 | DAHMS BRADFORD D | Chief Financial Officer | 37.81K | Stock Award(Grant) |
| 2024-07-31 | DAKE BENJAMIN T | President | 14.25K | Conversion of Exercise of derivative security |
| 2025-10-05 | FAIRMOUNT FUNDS MANAGEMENT LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Award(Grant) |
| 2026-02-11 | FROHLICH TOM | Chief Executive Officer | 86.33K | Stock Award(Grant) |
| 2026-02-11 | KING ANDREW JAMES | Officer | 386.11K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 7.09M | 154.53M | 14.35% |
| 2026-03-30 | Fairmount Funds Management LLC | 4.55M | 99.31M | 9.23% |
| 2026-03-30 | RA Capital Management, L.P. | 3.67M | 80.07M | 7.44% |
| 2026-03-30 | Bellevue Group AG | 3.50M | 76.37M | 7.09% |
| 2026-03-30 | Venrock Adviser, LLC | 3.22M | 70.24M | 6.52% |
| 2026-03-30 | Janus Henderson Group PLC | 3.11M | 67.73M | 6.29% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.39M | 30.21M | 2.81% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.01M | 22.03M | 2.05% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 767.76K | 16.74M | 1.56% |
| 2026-05-30 | Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 751.11K | 16.38M | 1.52% |
| 2026-04-29 | Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 693.70K | 15.13M | 1.41% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 640.00K | 13.96M | 1.30% |
Dividend
| Dividend | Date |
|---|---|
| 2.4 | 2025-04-29 |